NeurOp Revenue and Competitors
Estimated Revenue & Valuation
- NeurOp's estimated annual revenue is currently $1.1M per year.
- NeurOp's estimated revenue per employee is $155,000
Employee Data
- NeurOp has 7 Employees.
- NeurOp grew their employee count by 0% last year.
NeurOp's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Scientific Officer | Reveal Email/Phone |
2 | HEAD, CORPORATE DEVELOPMENT | Reveal Email/Phone |
NeurOp Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $1.7M | 11 | -8% | N/A | N/A |
#3 | $2.3M | 15 | 50% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $17.1M | 110 | 5% | $0.07B | N/A |
#6 | $4M | 26 | -7% | N/A | N/A |
#7 | $0.8M | 5 | 0% | N/A | N/A |
#8 | $1.1M | 7 | 17% | N/A | N/A |
#9 | $7.8M | 50 | 2% | N/A | N/A |
#10 | $1.7M | 11 | 10% | N/A | N/A |
What Is NeurOp?
NeurOp, Inc. is a clinical-stage, Atlanta-based biopharmaceutical company developing new medicines for central nervous system disorders, including severe pain, subarachnoid hemorrhage (SAH), and catastrophic juvenile epilepsies. Its technology targets the GluN2B subunit of neuronal NMDA receptors and its potential therapeutic benefit. Multi-year funding from the NIH supports NeurOp's research and development programs for NP10679, its drug candidate for the prevention of ischemic damage during a stroke or subarachnoid hemorrhage (SAH) and severe pain. For more information, please visit www.neuropinc.com
keywords:N/A
N/A
Total Funding
7
Number of Employees
$1.1M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Atlanta
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 7 | N/A | N/A |
#2 | $0.5M | 7 | N/A | N/A |
#3 | $0.5M | 7 | N/A | N/A |
#4 | $0.9M | 7 | N/A | N/A |
#5 | $0.5M | 7 | N/A | N/A |